MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jhlto.2024.100131

Медицинская библиотека · JHLT open · 2024

Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil.

Swaminathan Aparna C, Meservey Amber, Parish Alice, Green Cynthia L, Parikh Kishan, Fortin Terry, Krasuski Richard A, Whitson Jordan W, Dahhan Talal, Yu Yen-Rei, Kennedy Karla, Almeida-Peters Susana, Rajagopal Sudarshan

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Patients with pulmonary arterial hypertension (PAH) and additional cardiac or pulmonary comorbidities have a poor prognosis and are frequently excluded from clinical trials. The purpose of this study was to evaluate outcomes of patients with pulmonary hypertension (PH) secondary to a range of World Symposium on PH (WSPH) groups treated with inhaled treprostinil (iTRE) in a real-world setting.

METHODS

Patients with PH who were started on treatment with iTRE at Duke University were classified by WSPH Group and included patients with Groups 1, 2, 3, combined Groups 2 and 3 (PH in the setting of left heart failure and chronic lung disease), Group 4, and Group 5 PH. Time to disease worsening, a composite of death, lung transplantation, or transition to intravenous prostacyclin was compared by WSPH Group, and iTRE treatment status using a multivariable Cox proportional hazards model adjusted for age, sex, and Registry to Evaluate Early and Long-Term PAH Disease Management Lite 2 risk score. Treatment with iTRE was defined as a time-varying covariate.

RESULTS

The cohort included 270 patients with PH: 30.6% Group 1; 10% Group 2; 32.2% Group 3; 11.1% combined Groups 2 and 3; and 15.9% with either Group 4 or 5 PH. At 3 and 6 months of follow-up, 24.8% and 38.9% of patients, respectively, were no longer treated with iTRE. Patients who discontinued treatment with iTRE had a significantly higher risk of disease worsening (adjusted hazard ratio: 5.02, 95% confidence interval: 3.44-7.31). There was no significant difference in disease worsening among WSPH Groups.

CONCLUSIONS

In a real-world setting, many patients with PH secondary to a range of WSPH Groups tolerated treatment with iTRE. Future studies should phenotype patients with PH based on both comorbidities and therapeutic responsiveness.

Для цитирования: Swaminathan Aparna C, Meservey Amber, Parish Alice, Green Cynthia L, Parikh Kishan, Fortin Terry, Krasuski Richard A, Whitson Jordan W, Dahhan Talal, Yu Yen-Rei, Kennedy Karla, Almeida-Peters Susana, Rajagopal Sudarshan. Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil.. JHLT open. 2024. DOI: 10.1016/j.jhlto.2024.100131.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.